volume 26, issue 4, P893-901 2012
DOI: 10.1016/j.idc.2012.08.012
View full text

Abstract: In May 2011, the protease inhibitors boceprevir and telaprevir were approved in combination with peginterferon-α and ribavirin for the treatment of genotype 1 chronic hepatitis C virus infection in the United States. These regimens brought substantial improvements in sustained virologic response rates, especially for treatment-naïve patients. This article reviews the approach to therapy with these genotype 1 treatment-naïve patients.